XL JAK2
The XL JAK2 BA is designed as a break apart probe with two probes juxtaposed and differently labeled. An orange labeled probe hybridizes proximal, and a green labeled probe hybridizes distal to the breakpoint in 9p24.
Patients with clinical characteristics of CML lacking a BCR/ABL fusion gene are usually referred to as having atypical CML. Most commonly diverse tyrosine kinase genes as the receptors FGFR1, PDGFRA, or PDGFRB are involved. In addition the Janus (tyrosine) kinases (JAK) can be deregulated in leukemia/lymphoma by copy number alterations, mutations and chromosomal translocations.
Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities in myeloproliferative neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. In cell line models and primary patient material it could be shown that treatment with ruxolitinib has significant activity against JAK2 activated by gene rearrangement and presents evidence for potential activity against cells with JAK2 amplification.
Cena za kus: pro registrované
Patients with clinical characteristics of CML lacking a BCR/ABL fusion gene are usually referred to as having atypical CML. Most commonly diverse tyrosine kinase genes as the receptors FGFR1, PDGFRA, or PDGFRB are involved. In addition the Janus (tyrosine) kinases (JAK) can be deregulated in leukemia/lymphoma by copy number alterations, mutations and chromosomal translocations.
Chromosomal translocations targeting JAK2 are rare but recurrent abnormalities in myeloproliferative neoplasms, acute myeloid leukemia, acute lymphoblastic leukemia and lymphoma. In cell line models and primary patient material it could be shown that treatment with ruxolitinib has significant activity against JAK2 activated by gene rearrangement and presents evidence for potential activity against cells with JAK2 amplification.
Cena za kus: pro registrované
